BRIDGEBIO PHARMA INC (BBIO) Institutional Ownership

BBIO is currently held by 3 institutional investors tracked by InsiderSet, with a combined reported market value of approximately $909.99M based on the latest available SEC Form 13F filings for the quarter ended March 31, 2026.

The largest disclosed holder is Viking Global Investors, which reported ownership valued at approximately $879.42M in its March 31, 2026 13F filing. Based on current market prices and the latest disclosed share count, Viking Global Investors's BBIO position is now estimated to be worth approximately $798.06M, representing an estimated loss of -9.25% since the filing period.

Major shareholders tracked on this page include Viking Global Investors, Renaissance Technologies LLC, Polen Capital Management, and other prominent asset managers. Collectively, these investors account for approximately 100% of the total disclosed value among the investors covered in this analysis.

This page tracks fund ownership trends, hedge fund exposure, portfolio concentration, historical 13F filings, and estimated holding performance to help investors analyze smart money sentiment toward BRIDGEBIO PHARMA INC (BBIO).

Institutional Ownership Trend

Portfolio quarterInstitutional holdersTotal reported valueTotal shares
Q1 20263$909,992,43712,254,140
Q4 20253$1,104,156,78614,435,309
Q3 20253$848,505,29216,336,259
Q2 20253$813,380,36518,836,970
Q1 20251$762,454,31422,055,375
Q4 20241$689,319,99325,120,991
Q3 20241$639,580,43125,120,991
Q2 20241$636,314,70225,120,991
Q1 20241$776,741,04225,120,991
Q4 20231$1,014,134,40725,120,991
Q3 20232$662,455,93725,705,137
Q2 20231$457,881,04526,620,991

Related BBIO Institutional Insights: